Mysite 사이트 그룹

French service providers have integrated Artificial Intelligence into the early-stage drug discovery process. Biotech firms now outsource "In Silico" screening to French specialized firms that use supercomputing clusters to model drug-protein interactions.

These services allow companies to identify the most promising lead compounds in a matter of weeks rather than years. By outsourcing the computational heavy lifting to French tech-bio firms, pharmaceutical companies can significantly reduce their R&D overhead and focus their resources on the clinical stages of development.